IPA
Price
$0.52
Change
-$0.05 (-8.93%)
Updated
Jun 4, 02:26 PM (EDT)
Capitalization
25.79M
LPCN
Price
$3.27
Change
+$0.07 (+2.19%)
Updated
Jun 4, 12:42 PM (EDT)
Capitalization
17.55M
Interact to see
Advertisement

IPA vs LPCN

Header iconIPA vs LPCN Comparison
Open Charts IPA vs LPCNBanner chart's image
ImmunoPrecise Antibodies
Price$0.52
Change-$0.05 (-8.93%)
Volume$5K
Capitalization25.79M
Lipocine
Price$3.27
Change+$0.07 (+2.19%)
Volume$175
Capitalization17.55M
IPA vs LPCN Comparison Chart
Loading...
IPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LPCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IPA vs. LPCN commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IPA is a Hold and LPCN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (IPA: $0.56 vs. LPCN: $3.20)
Brand notoriety: IPA and LPCN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IPA: 54% vs. LPCN: 24%
Market capitalization -- IPA: $25.79M vs. LPCN: $17.55M
IPA [@Biotechnology] is valued at $25.79M. LPCN’s [@Biotechnology] market capitalization is $17.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IPA’s FA Score shows that 1 FA rating(s) are green whileLPCN’s FA Score has 0 green FA rating(s).

  • IPA’s FA Score: 1 green, 4 red.
  • LPCN’s FA Score: 0 green, 5 red.
According to our system of comparison, IPA is a better buy in the long-term than LPCN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IPA’s TA Score shows that 4 TA indicator(s) are bullish while LPCN’s TA Score has 4 bullish TA indicator(s).

  • IPA’s TA Score: 4 bullish, 4 bearish.
  • LPCN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, IPA is a better buy in the short-term than LPCN.

Price Growth

IPA (@Biotechnology) experienced а +5.52% price change this week, while LPCN (@Biotechnology) price change was -9.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.51%. For the same industry, the average monthly price growth was +5.30%, and the average quarterly price growth was -2.02%.

Reported Earning Dates

IPA is expected to report earnings on Mar 28, 2025.

LPCN is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+6.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IPA($25.8M) has a higher market cap than LPCN($17.5M). IPA YTD gains are higher at: 36.872 vs. LPCN (-34.426). LPCN has higher annual earnings (EBITDA): -3.68M vs. IPA (-45.11M). LPCN has more cash in the bank: 19.8M vs. IPA (12.9M). LPCN has less debt than IPA: LPCN (1.48M) vs IPA (12.9M). IPA has higher revenues than LPCN: IPA (24M) vs LPCN (7.92M).
IPALPCNIPA / LPCN
Capitalization25.8M17.5M147%
EBITDA-45.11M-3.68M1,226%
Gain YTD36.872-34.426-107%
P/E RatioN/AN/A-
Revenue24M7.92M303%
Total Cash12.9M19.8M65%
Total Debt12.9M1.48M870%
FUNDAMENTALS RATINGS
IPA vs LPCN: Fundamental Ratings
IPA
LPCN
OUTLOOK RATING
1..100
1177
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9692
PRICE GROWTH RATING
1..100
3863
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IPA's Valuation (23) in the null industry is in the same range as LPCN (40) in the Pharmaceuticals Other industry. This means that IPA’s stock grew similarly to LPCN’s over the last 12 months.

IPA's Profit vs Risk Rating (100) in the null industry is in the same range as LPCN (100) in the Pharmaceuticals Other industry. This means that IPA’s stock grew similarly to LPCN’s over the last 12 months.

LPCN's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as IPA (96) in the null industry. This means that LPCN’s stock grew similarly to IPA’s over the last 12 months.

IPA's Price Growth Rating (38) in the null industry is in the same range as LPCN (63) in the Pharmaceuticals Other industry. This means that IPA’s stock grew similarly to LPCN’s over the last 12 months.

LPCN's P/E Growth Rating (97) in the Pharmaceuticals Other industry is in the same range as IPA (100) in the null industry. This means that LPCN’s stock grew similarly to IPA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IPALPCN
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 20 days ago
84%
Declines
ODDS (%)
Bearish Trend 27 days ago
90%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
IPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LPCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRZO0.980.07
+7.62%
ParaZero Technologies Ltd
EME483.7814.23
+3.03%
EMCOR Group
OCFC17.070.37
+2.22%
OceanFirst Financial Corp
TSBK30.25-0.17
-0.56%
Timberland Bancorp
CNX31.90-0.38
-1.18%
CNX Resources Corp